Pyrazole

Pyrazole

SCHEMBL4098397

O=C(O)c1cc[nH]c(=O)n1.c1cn[nH]c1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ACMSD Q8TDX5 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 3/20 0.35
KMT2A Q03164 2/20 0.35
KDM5A P29375 1/20 0.35
JMJD1C Q15652 1/20 0.35
KDM3A Q9Y4C1 1/20 0.35
MEN1 O00255 1/20 0.35
MGAM O43451 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
NAPRT Q6XQN6 2/20 0.33
P4HTM Q9NXG6 1/20 0.33
KEAP1 Q14145 1/20 0.33
ECE1 P42892 1/20 0.31
GNE Q9Y223 1/20 0.30
GRM5 P41594 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrazole SCHEMBL4574957 0.85
SCHEMBL4102491 0.85 KDM4E (0.48) KDM4EALOX15TSHRACMSDTDP1
Pyrazole SCHEMBL29392444 0.77 LMNA (0.37) KDM4EALOX15TSHRACMSDTDP1
2-Picolinic Acid SCHEMBL9805822 0.72 LMNA (0.69) KDM4EALOX15TSHRACMSDTDP1
Pyrazole SCHEMBL5064075 0.71 HCAR2 (0.31)
Pyrazole SCHEMBL20495491 0.71
Benzoic Acid SCHEMBL14918555 0.71 NAPRT (0.56) KDM4ETSHRLMNAKMT2AKDM3A
SCHEMBL8587424 0.70 MAPT (0.50) KDM4EALOX15TDP1KMT2AMEN1
SCHEMBL2785730 0.69 MAPK1 (0.42) KDM4E
Oxalic Acid SCHEMBL27705066 0.69 HCAR2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215778-A1 Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives PANACOS PHARMACEUTICALS, INC. (US) 2009-08-27 US disclosed
WO-2008134036-A1 ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES PANACOS PHARMACEUTICALS, INC. (US) 2008-11-06 WO disclosed
WO-2008134035-A1 ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES PANACOS PHARMACEUTICALS, INC. (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215778-A1 Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives THPO, DPYD, TPMT KDM4E 3298/4885ALOX15 3217/4885TSHR 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.